Oragenics Files 8-K Report

Ticker: OGEN · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1174940

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Oragenics filed an 8-K on Feb 5, 2025, likely with financial updates. Check for details.

AI Summary

On February 5, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and other significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.

Why It Matters

This filing signals that Oragenics, Inc. has made a regulatory disclosure, potentially containing important updates for investors regarding financial statements or other material events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K disclosure without immediate indication of significant financial distress or major operational changes.

Key Players & Entities

FAQ

What specific "Other Events" are being reported by Oragenics, Inc. in this 8-K filing?

The provided excerpt does not detail the specific "Other Events" being reported, only that this item is included in the filing.

What "Financial Statements and Exhibits" are included with this 8-K filing?

The excerpt states that "Financial Statements and Exhibits" are part of the filing, but does not list their specific contents.

What is the principal executive office address for Oragenics, Inc.?

The principal executive offices of Oragenics, Inc. are located at 1990 Main Street, Suite 750, Sarasota, FL 34236.

What is the telephone number for Oragenics, Inc.?

The telephone number for Oragenics, Inc. is 813-286-7900.

What is the SIC code for Oragenics, Inc.?

The Standard Industrial Classification (SIC) code for Oragenics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2025-02-05 08:00:12

Filing Documents

SIGNATURES

SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 5 th day of February 2025. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing